Guided Therapeutics (GTHP) Capital Expenditures Growth (3y) (2014 - 2022)
Guided Therapeutics (GTHP) Capital Expenditures Growth (3y) (2014 - 2022) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 1.64% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 8.49% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 8.89% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 16.83% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 1.81% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 0.84% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 2.15% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 7.57% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Guided Therapeutics | 21.96 Mn | 21.89 Mn | 458,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 71.00% |
| Sep 30, 2021 | -31.27% |
| Jun 30, 2021 | 28.49% |
| Mar 31, 2021 | 28.28% |
| Sep 30, 2020 | 61.55% |
| Dec 31, 2019 | -26.44% |
| Sep 30, 2018 | 91.29% |
| Jun 30, 2018 | -154.58% |
| Mar 31, 2018 | -4.00% |
| Sep 30, 2017 | -20.47% |
| Mar 31, 2017 | -31.04% |
| Dec 31, 2016 | 30.37% |
| Sep 30, 2016 | -58.74% |
| Mar 31, 2016 | -29.63% |
| Dec 31, 2015 | 26.11% |
| Sep 30, 2015 | -56.42% |
| Jun 30, 2015 | -26.08% |
| Mar 31, 2015 | 60.52% |
| Sep 30, 2014 | 9.28% |
| Jun 30, 2014 | 3.64% |